Menu Search
Equities

Scope Fluidics SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
S84:DUS

Scope Fluidics SA

Actions
  • Price (EUR)30.45
  • Today's Change0.05 / 0.16%
  • Shares traded3.00
  • 1 Year change-20.81%
  • Beta-0.2508
Data delayed at least 15 minutes, as of Feb 11 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Scope Fluidics SA is a Poland-based company engaged in the biotechnology. The Company focuses on diagnostic and med-tech solutions. It develops disposable microfluidic systems for the collection of micro-samples of blood, as well as storage of reagents for diagnostic markers. Its projects include PCR ONE system that delivers the bacterial and viral pathogen detection, and BacterOMIC system that delivers information on bacterial susceptibility to antibiotics and on the resistance mechanisms. The Company provides access to laboratories and workshops for developed projects, as well as administrative facilities and services, including financing. In addition, it cooperates with doctors, medical personnel, project managers, engineers and academics.

  • Revenue in PLN (TTM)718.00k
  • Net income in PLN54.47m
  • Incorporated2017
  • Employees132.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.